European thrombosis market in urgent need for enhanced products, says F&S

The increasing incidence of thrombosis, paralleled by the maturing life cycles of existing products, are motivating the need for novel alternatives. Establishing end-user confidence and ensuring cost-effectiveness pose significant challenges to market advancement. However, the launch of three blockbuster oral anticoagulants is projected to help the thrombosis therapeutics market address these challenges. It is also anticipated to help companies tackle competition from low cost generics.

New analysis from Frost & Sullivan, titled Analysis of the European Thrombosis Therapeutics Market, finds that the market earned revenues of approximately $8.67 billion in 2010 and estimates this to reach around $13.01 billion in 2017 at a compound annual growth rate (CAGR) of 6.6% from 2010-2017.

“The rising number of people suffering from thrombosis is resulting in higher demand for related therapeutics,” notes Frost & Sullivan research analyst Deepika Pramod Chopda, adding: “This, coupled with strong pipeline development, is pushing robust growth in the overall market.”